Valuation : Protalix BioTherapeutics, Inc.

Market Cap 22Cr 0 19Cr 17Cr 16Cr 30Cr 2.05TCr 30Cr 206.58Cr 80Cr 1.04TCr 81Cr 79Cr 3.3TCr P/E 2026 *
11.1x
P/E 2027 * 53.4x
Enterprise Value 22Cr 0 19Cr 17Cr 16Cr 30Cr 2.05TCr 30Cr 206.58Cr 80Cr 1.04TCr 81Cr 79Cr 3.3TCr EV / Sales 2026 *
2.62x
EV / Sales 2027 * 3.24x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 22Cr
+0.03%-3.09%+49.77%+91.69% 1,00200Cr
-0.76%-2.95%+50.93%+66.34% 64TCr
+0.86%-4.13%+19.24%+68.37% 44TCr
-0.29%-2.92%+30.06%+36.31% 34TCr
+1.78%-13.84%+12.31%+28.12% 26TCr
-0.07%-4.01%-2.14%+11.02% 24TCr
-0.48%-11.65%+39.75%+50.82% 21TCr
+0.34%-4.31%-17.83%-57.81% 20TCr
-0.68%-2.65%+25.82%+91.64% 18TCr
Average -0.07%-5.00%+23.10%+42.95% 39.22TCr
Weighted average by Cap. -0.11%-4.24%+32.22%+57.58%

Financials

2026 *2027 *
Net sales 8.22Cr 0 7.07Cr 6.66Cr 6.07Cr 11Cr 781.78Cr 11Cr 79Cr 30Cr 398.28Cr 31Cr 30Cr 1.26TCr 6.65Cr 0 5.72Cr 5.39Cr 4.91Cr 9.18Cr 632.6Cr 9.22Cr 64Cr 25Cr 322.28Cr 25Cr 24Cr 1.02TCr
Net income 1.96Cr 0 1.69Cr 1.59Cr 1.45Cr 2.71Cr 186.81Cr 2.72Cr 19Cr 7.29Cr 95Cr 7.37Cr 7.21Cr 301.5Cr 37.94L 0 32.65L 30.74L 28.01L 52.41L 36Cr 52.62L 3.64Cr 1.41Cr 18Cr 1.42Cr 1.39Cr 58Cr
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.670USD
Average target price
11.00USD
Spread / Average Target
+311.99%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!